Comparison of Laboratory Test Results of Minimal-Residual Disease in Samples From Patients With Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01498302|
Recruitment Status : Completed
First Posted : December 23, 2011
Last Update Posted : July 11, 2016
RATIONALE: Diagnostic procedures that find residual disease may help predict if the disease will come back in patients diagnosed with acute myeloid leukemia.
PURPOSE: This research trial studies the comparison of laboratory test results for minimal residual disease in samples from patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Other: diagnostic laboratory biomarker analysis Other: flow cytometry|
- To promote harmonization between Cooperative Group Reference Laboratories conducting minimal-residual disease (MRD) evaluation of acute myeloid leukemia by flow cytometry.
OUTLINE: Archived bone marrow and blood samples, distributed to the Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B laboratories, are analyzed for leukemia-associated immunophenotype (LAIP) assays and minimal residual disease studies by flow cytometry. Results are then provided to the National Cancer Institute for assessment and comparability of test results.
|Study Type :||Observational|
|Estimated Enrollment :||10 participants|
|Official Title:||Interlaboratory Comparability Study of Residual Disease in Acute Myelogenous Leukemia|
|Study Start Date :||February 2012|
|Actual Primary Completion Date :||July 2016|
- Degree of concordance in the MRD assay results between laboratories
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01498302
|Principal Investigator:||J. Milburn Jessup, MD||National Cancer Institute (NCI)|